Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleEndocrinology

Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis

Julia Whitman, Isabel E. Allen, Emily K. Bergsland, Insoo Suh and Thomas A. Hope
Journal of Nuclear Medicine September 2021, 62 (9) 1285-1291; DOI: https://doi.org/10.2967/jnumed.120.257303
Julia Whitman
1Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel E. Allen
2Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily K. Bergsland
1Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California;
3Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Insoo Suh
4Department of Surgery, University of California San Francisco, San Francisco, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas A. Hope
3Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California;
5Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; and
6Department of Radiology, San Francisco VA Medical Center, San Francisco, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    PRISMA (Preferred Reporting Items for Systematic Review and Metaanalysis) flow diagram depicting process for selecting papers included in this metaanalysis.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Summary of sensitivity, specificity, and hierarchic summary receiver-operating-characteristic (HSROC) plot of sensitivity and specificity for 18F-FCH vs. pathology overall. Effect sizes for sensitivity and specificity were 0.97 (95% CI, 0.96–0.98) and 0.23 (95% CI, 0.11–0.35), respectively. Size of circles represents size of individual studies.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Summary of sensitivity, specificity, and hierarchic summary receiver-operating-characteristic (HSROC) plot of sensitivity and specificity for 99mTc-sestamibi vs. pathology overall. Effect sizes for sensitivity and specificity were 0.54 (0.29–0.79) and 0.43 (0.30–0.57), respectively. Size of circles represents size of individual studies.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Comparison of diagnostic sensitivities of 18F-FCH and 99mTc-sestamibi. Overall effect sizes (ES) were 0.96 (95% CI, 0.94–0.98) for 18F-FCH PET and 0.54 (95% CI, 0.29–0.79) for 99mTc-sestamibi. Size of squares represents size of individual studies. Reference numbers are in Supplemental Table 2.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Characteristics of Studies Included in Metaanalysis (23–44)

    First author Year Prospective or retrospective? NCT number Consent obtainedPatients with 18F-FCH imaging Patients with parathyroidectomy Masked readers Readers Pathology correlation PET/CT or PET/MRI?Injected dose range (MBq)Injected dose average (MBq) Uptake time (min) Primary HPT only?
    Alharbi2018RetrospectiveNoYes6652No2YesBothNR1502 & 50Yes
    Amadou2019RetrospectiveNoNo4123NoNRYesPET/CTNR23160Yes
    Bossert2019ProspectiveNoYes3417Unclear2YesPET/CTNR3–3.5/kg9 & 60Yes
    Broos2019ProspectiveNoYes271139Yes3YesPET/CTNR1505 & 60Yes
    Christakis2019ProspectiveNoYes1212Yes1YesPET/CTNR30060 & 90Yes
    Fischli2017RetrospectiveNoYes3923No1YesPET/CTIQR 180–14916045Yes
    Grimaldi2018ProspectiveNoNo2721UnclearNRYesPET/CT77–23010030Yes
    Hocevar2017RetrospectiveNoNo151151NoNRYesPET/CTNR1005 & 60Yes
    Huber2018RetrospectiveNoYes2626UnclearNRYesBothNR15145No
    Khafif2019ProspectiveNoYes1919No2YesPET/MRINR93.7516Yes
    Kluijfhout2017ProspectiveNoYes1010Yes2YesPET/MRI188 ± 261880*Yes
    Kluijfhout2016RetrospectiveNoYes3333UnclearNRYesPET/CTNR2/kg30No
    Lezaic2014ProspectiveNoYes2424Unclear2YesPET/CTNR1005 & 60Yes
    López-Mora2020ProspectiveNoYes3333Unclear3YesPET/CT: digital vs. analogNR0.1/kgUnclearYes
    Michaud2014ProspectiveNoYes1212No1YesPET/CTNR3/kg0†No
    Piccardo2019ProspectiveNoYes4431Unclear2YesPET/CTNR10010Yes
    Quak2018ProspectiveNCT02432599Yes2524YesNRYesPET/CTNR1.5/kg60Yes
    Thanseer2017ProspectiveNoYes5454UnclearNRYesPET/CT150–185150–18510–15 & 60Yes
    Uslu-Beşli2020RetrospectiveNoYes10581No2YesPET/CT325.1 ± 86.7325.115 & 45No
    Zajíčková2018RetrospectiveNoYes1313Unclear2YesPET/CTNR18030Yes
    • ↵* Dynamic imaging for 40 min.

    • ↵† Dynamic imaging for 10 min followed by static acquisition.

    • NCT = National Clinical Trial; HPT = hyperparathyroidism; NR = not reported; IQR = interquartile range.

    • View popup
    TABLE 2

    Overview of Studies Comparing Performance of 18F-FCH PET with Pathology in 20 Studies Reporting Total of 796 Patients

    First authorYearPatientsTPFPTNFN
    Alharbi20185252000
    Amadou20192321101
    Bossert20191715002
    Broos2019139131026
    Christakis2019127500
    Fischli201723211NA1
    Grimaldi201821171NA3
    Hocevar2017151144412
    Huber20182625001
    Khafif20191919000
    Kluijfhout20171090NA1
    Kluijfhout201633301NA2
    Lezaic201424230NA1
    López-Mora20203329103
    Michaud201412110NA1
    Piccardo20193125006
    Quak201824193NA2
    Thanseer201754522NA0
    Uslu-Beşli20207976NANA3
    Zajíčková20181312001
    Total79673819333
    • TP = true positive; FP = false positive; TN = true negative; FN = false negative; NA = not applicable.

    • View popup
    TABLE 3

    Overview of Studies Comparing Performance of 99mTc-Sestamibi with Pathology

    99mTc-sestamibi compared with pathology
    First authorYearPatients with pathologyTPFPTNFN
    Amadou20192391013
    Bossert20191730014
    Huber20182620024
    Khafif20191917002
    Kluijfhout20173380021
    Lezaic201424140010
    Michaud2014128202
    Thanseer201754421110
    Uslu-Beşli202080391NANA
    Zajíčková2018134207
    Total30114671103
    • TP = true positive; FP = false positive; TN = true negative; FN = false negative; NA = not applicable.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (9)
Journal of Nuclear Medicine
Vol. 62, Issue 9
September 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis
Julia Whitman, Isabel E. Allen, Emily K. Bergsland, Insoo Suh, Thomas A. Hope
Journal of Nuclear Medicine Sep 2021, 62 (9) 1285-1291; DOI: 10.2967/jnumed.120.257303

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis
Julia Whitman, Isabel E. Allen, Emily K. Bergsland, Insoo Suh, Thomas A. Hope
Journal of Nuclear Medicine Sep 2021, 62 (9) 1285-1291; DOI: 10.2967/jnumed.120.257303
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Diagnostic Performance of Cervical Ultrasound, 99mTc-Sestamibi Scintigraphy, and Contrast-Enhanced 18F-Fluorocholine PET in Primary Hyperparathyroidism
  • Google Scholar

More in this TOC Section

  • Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW
  • 18F-Fluorocholine PET/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands
Show more Endocrinology

Similar Articles

Keywords

  • fluorocholine
  • hyperparathyroidism
  • adenoma
  • PET
  • 99mTc-sestamibi
SNMMI

© 2025 SNMMI

Powered by HighWire